stratified man

Protagen Precision Diagnostics

Protagen specializes in Pharma development services, novel diagnostics and companion diagnostics, in the fields of immuno-oncology and autoimmune disease. Using its proprietary SeroTag® biomarker discovery platform and its portfolio of NavigAID patient stratification products, Protagen identifies valuable biomarkers that support pharmaceutical development and personalized treatment with targeted therapies. Utilizing pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen is expanding its own pipeline of critically informative biomarkers and collaborates with other organizations to commercialize valuable tools for better personalized treatment strategies.

Autoimmune and Immuno-oncology

The ability to stratify patients into different disease subgroups based on the individual molecular characteristics of each subtype can drive better drug development and improve the success rate of clinical trials. Protagen’s SeroTag® technology has been applied in the development of the NavigAID portfolio of patient stratification arrays for autoimmune indications such as SSc. SLE, RA and SJS.

Protagen’s SeroTag® technology is also being applied to the field of immuno-oncology where it is helping pharmaceutical and biotechnology companies to address, identify and monitor a number of issues currently hindering the successful development and broader application of certain cancer immunotherapies, such as low response rates and immune-related adverse events (irAEs) and the onset of autoimmune disease. Protagen also aims to develop NavigAID for immuno-oncology application.

News

Protagen AG join forces with the U.S. National Cancer Institute to answer pressing questions in immuno-oncology

Protagen AG has executed a Material Transfer Agreement with the National Cancer Institute (NCI) under which the parties will utilize Protagen's SeroTag® immune system profiling technology to identify biomarkers that predict therapy responsiveness, to monitor patients receiving immunotherapies, and for early detection of immune-related adverse events (irAEs). This collaboration with NCI will be led by Jeffrey Schlom, Ph.D., Chief of the Laboratory of Tumor Immunology and Biology at the NCI’s Center for Cancer Research.

The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Investigate Responsiveness to Checkpoint Inhibitors in Melanoma

The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG today announced a collaboration to utilize Protagen’s SeroTag® technology to identify biomarkers that predict therapy responsiveness and the detection of immune-related adverse events (irAEs) in melanoma patients treated with checkpoint inhibitors.

Protagen AG successfully joined forces with Novartis to support Clinical Development of a Novel Compound in an Autoimmune Indication

PROTAGEN AG, a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced the successful completion of a collaboration agreement with Novartis Pharma AG. During the collaboration, Protagen utilized its proprietary SeroTag technology to discover prediction as well as patient stratification markers for a novel drug being developed by Novartis.